Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naive Japanese patients with type 2 diabetes

被引:6
|
作者
Ohta, Akio [1 ]
Ohshige, Toshihiko [1 ]
Sakai, Kensuke [1 ]
Nakamura, Yuta [1 ]
Tenjin, Ayumi [1 ]
Tsukiyama, Shuichi [1 ]
Terashima, Yuko [1 ]
Matsubara, Fumiaki [1 ]
Kawata, Takehiro [1 ]
Nagai, Yoshio [1 ]
Tanaka, Yasushi [1 ]
机构
[1] St Marianna Univ, Sch Med, Div Endocrinol & Metab, Dept Internal Med,Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan
关键词
1,5-anhydroglucitol; glycoalbumin; mitiglinide; sitagliptin; voglibose; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; ALPHA-GLUCOSIDASE INHIBITORS; FASTING PLASMA-GLUCOSE; FIXED-DOSE COMBINATION; INSULIN-SECRETION; POSTPRANDIAL HYPERGLYCEMIA; NATEGLINIDE; SULFONYLUREAS; RESISTANCE; RISK;
D O I
10.1517/14656566.2013.842554
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The postprandial glucose (PPG) level is reduced by alpha-GIs, glinides and DPP4Is through different pharmacological actions. The aim of this study was to compare the effect of sitagliptin (S) versus that of the combination of mitiglinide and voglibose (M+V) on markers of glycemic control. Research design and methods: A randomized cross-over trial was performed in 20 patients with drug-naive type 2 diabetes. The patients were randomized to receive S (50 mg/day) or M+V (1 tablet 3 times daily). Treatment was continued for 8 weeks, after which they were switched to the other regimen and treated for another 8 weeks. At baseline, after the first regimen, and after the second regimen, a meal test was performed. Main outcome measures: The markers of glycemic control were examined. Results: Reduction of glucose excursion was significantly greater with M+V than with S. HbA(1c) did not change with either regimen. However, 1,5-anhydroglucitol showed a significant increase from baseline with both regimens (7.9 +/- 4.3 mu g/ml at baseline vs. 10.6 +/- 5.5 with S, p < 0.05 and 15.1 +/- 6.2 with M+V, p < 0.01). Compared with baseline, glycoalbumin was significantly reduced by M+V, but not S (19.6 +/- 2.9% at baseline vs. 17.3 +/- 3.8% with M+V, p < 0.05). Conclusion: M+V achieved better control of PPG excursion than S.
引用
收藏
页码:2315 / 2322
页数:8
相关论文
共 50 条
  • [1] Comparison of the Efficacy of Repaglinide versus the Combination of Mitiglinide and Voglibose on Glycemic Variability in Japanese Patients with Type 2 Diabetes
    Okada, Hiroshi
    Tanaka, Muhei
    Hasegawa, Goji
    Nakajima, Hanako
    Kadono, Mayuko
    Okada, Yuki
    Hirata, Atsuhiro
    Oyamada, Hirokazu
    Yamane, Tetsuro
    Fukui, Michiaki
    CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (43) : 4600 - 4605
  • [2] Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin versus pioglitazone in drug-naive patients with type 2 diabetes
    Perez-Monteverde, A.
    Seck, T.
    Xu, L.
    Liu, G.
    Lee, M. A.
    Sisk, C. McCrary
    Williams-Herman, D. E.
    Kaufman, K. D.
    Goldstein, B. J.
    DIABETOLOGIA, 2010, 53
  • [3] Effects of gemigliptin versus sitagliptin or glimepiride on glycaemic variability as initial combination therapy with metformin in drug-naive patients with type 2 diabetes
    Lee, B. -W.
    Kim, J.
    Park, S.
    Jung, C.
    Lee, S. -H.
    Suh, S.
    Lee, W.
    Cho, J. -H.
    Jang, Y.
    Kim, S. -H.
    Park, C. -Y.
    DIABETOLOGIA, 2015, 58 : S387 - S387
  • [4] EFFECTS OF GEMIGLIPTIN VERSUS SITAGLIPTIN OR GLIMEPIRIDE ON GLYCEMIC VARIABILITY AS INITIAL COMBINATION THERAPY WITH METFORMIN IN DRUG-NAIVE PATIENTS WITH TYPE 2 DIABETES
    Park, S. E.
    Lee, B. -W.
    Kim, J. H.
    Jung, C. H.
    Lee, S. -H.
    Suh, S. H.
    Lee, W. J.
    Jang, Y. H.
    Kim, S. -H.
    Park, C. -Y.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S139 - S139
  • [5] Initial combination of metformin, sitagliptin, and empagliflozin in drug-naive patients with type 2 diabetes: Safety and metabolic effects
    Lim, Soo
    Sohn, Minji
    Shin, Yujin
    Ferrannini, Ele
    DIABETES OBESITY & METABOLISM, 2022, 24 (04): : 757 - 762
  • [6] Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Lobeglitazone in Drug-Naive Patients with Type 2 Diabetes
    Kim, Kyoung Min
    Lee, Seo Young
    Lee, Ji Hyun
    Lee, Dong Hwa
    Oh, Tae Jung
    Jang, Hak Chul
    Lim, Soo
    DIABETES, 2017, 66 : A346 - A346
  • [7] Comparison of sitagliptin with nateglinide on postprandial glucose and related hormones in drug-naive Japanese patients with type2 diabetes mellitus: A pilot study
    Tanimoto, Masumi
    Kanazawa, Akio
    Hirose, Takahisa
    Yoshihara, Tomoaki
    Kobayashi-Kimura, Saeko
    Nakanishi, Risa
    Tosaka, Yuka
    Sasaki-Omote, Ruri
    Kudo-Fujimaki, Kyoko
    Komiya, Koji
    Ikeda, Fuki
    Someya, Yuki
    Mita, Tomoya
    Fujitani, Yoshio
    Watada, Hirotaka
    JOURNAL OF DIABETES INVESTIGATION, 2015, 6 (05) : 560 - 566
  • [8] Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naive patients with type 2 diabetes
    Perez-Monteverde, A.
    Seck, T.
    Xu, L.
    Lee, M. A.
    Sisk, C. M.
    Williams-Herman, D. E.
    Engel, S. S.
    Kaufman, K. D.
    Goldstein, B. J.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (09) : 930 - 938
  • [9] Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus
    Katsuno, Tomoyuki
    Watanabe, Nobuaki
    Nagai, Etsuko
    Okazaki, Kazumi
    Yokoyama, Ariko
    Hamaguchi, Tomoya
    Miyagawa, Jun-ichiro
    Namba, Mitsuyoshi
    JOURNAL OF DIABETES INVESTIGATION, 2011, 2 (03) : 204 - 209
  • [10] Effect of short-term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug-naive Japanese patients with type 2 diabetes mellitus
    Suzuki, Ryo
    Eiki, Jun-ichi
    Moritoyo, Takashi
    Furihata, Kenichi
    Wakana, Akira
    Ohta, Yukari
    Tokita, Shigeru
    Kadowaki, Takashi
    DIABETES OBESITY & METABOLISM, 2018, 20 (09): : 2274 - 2281